Key Developments
On February 1, 2022, AbbVie, a U.S.-based pharmaceutical company, announced that it will continue in research in inflammatory bowel diseases with new analyses on HUMIRA (adalimumab) and the investigational uses of risankizumab (SKYRIZI) and upadacitinib (RINVOQ) at the 17th Congress of European Crohn's and Colitis Organisation (ECCO). Achievement of steroid-free remission in patients with moderately to severely active Crohn's disease during treatment with risankizumab digital oral presentation. Normalization of biomarkers and improvement in clinical outcomes in patients with Crohn's disease treated with risankizumab in the Phase 3.
On October 26, 2020, Samsung Bioepis Co., Ltd. announced results from two real-world studies of RENFLEXIS (infliximab-abda) in patients with Inflammatory Bowel Disease (IBD) registered in the U.S. Veteran Affairs Healthcare System database. The data were presented for the first time at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting, which is held virtually from October 23 to 28, 2020.
On January 27, 2020, AstraZeneca, a pharmaceutical company announced the recovery for the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is in a Phase IIb/III programme in Crohn's disease (CD) and a Phase IIb trial in ulcerative colitis. Brazikumab is a monoclonal antibody that binds to the IL23 receptor and is in development for CD and UC with a companion biomarker. Brazikumab selectively blocks the IL23 immune signal, preventing intestinal inflammation. In Phase II trials, it demonstrated a clinical effect at week eight in tumor necrosis factor-resistant CD patients.
On February 18, 2021, Crohn's & Colitis Foundation, based in the U.K., explained the integration of mind-body treatment models into conventional healthcare is becoming the norm and not the exception, including for the treatment of chronic visceral pain. The brain-gut axis is a two-way superhighway; now recognize that the central nervous system (located in the brain and spinal cord) is constantly communicating with the messengers to and from the peripheral nervous system throughout the body. So, treatments that focus on the mind (including hypnosis, cognitive behavioral therapy, biofeedback, and mindfulness) are increasingly used to alter the way we process pain messages.
Visceral Pain Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients